Why Secretagogues Instead of HGH
Exogenous HGH suppresses the body's own production and blunts the feedback loop. Secretagogues work within the axis, preserve pulsatility, and are far easier to taper off.
Peptide Therapy · Growth Hormone Support
CJC-1295 / Ipamorelin
A paired secretagogue protocol that supports your own growth hormone rhythm.
CJC-1295 is a growth hormone-releasing hormone analog; Ipamorelin is a selective ghrelin-receptor agonist. Together they raise endogenous growth hormone output in pulses that follow your natural nightly pattern, rather than replacing it with exogenous HGH.
2
Complementary pathways
GHRH analog plus ghrelin-receptor agonist
5
Nights per week
Two nights off preserves receptor sensitivity
12
Week initial cycle
Reassessed with labs before continuing
Clinical Benefits
What CJC-1295 / Ipamorelin Does in the Body
Pulsatile, Not Replacement
Stimulates your pituitary to release its own growth hormone in physiologic pulses instead of overriding the axis with exogenous HGH.
Sleep Quality
Growth hormone release is tied to slow-wave sleep; patients commonly report deeper sleep within the first few weeks.
Lean Mass Support
Useful alongside a GLP-1 protocol, where the goal is losing fat while defending muscle.
Recovery Capacity
Supports connective-tissue repair and day-to-day recovery from training load.
Selective Signaling
Ipamorelin is highly selective — minimal effect on cortisol or prolactin compared with older secretagogues.
Skin and Body Composition
Patients frequently report gradual changes in skin quality and waist measurement over a full cycle.
Mechanism of Action
How It Actually Works
The two peptides act on separate receptors that converge on the same pituitary output. Used together, they produce a larger and cleaner growth hormone pulse than either alone.
- 01
GHRH Signal
CJC-1295 binds the GHRH receptor, increasing the amplitude of each pituitary pulse.
- 02
Ghrelin Receptor Signal
Ipamorelin activates the GHS-R1a receptor and suppresses somatostatin, the brake on release.
- 03
Nightly Pulse
Dosed at bedtime, the combination aligns with the body's largest natural GH pulse in slow-wave sleep.
- 04
Downstream IGF-1
Hepatic IGF-1 rises modestly, which is the marker your physician tracks on follow-up labs.
Education
What Your Physician Wants You to Understand
Labs Are Not Optional
We check IGF-1, fasting glucose and A1c before starting and again at follow-up. Growth hormone signaling affects insulin sensitivity, and that is monitored, not assumed.
Where the Evidence Stands
Both peptides have published human pharmacokinetic and endocrine data showing reliable GH and IGF-1 elevation. Long-duration outcome trials in healthy adults are limited, and it is prescribed off-label.
Athletic Testing Note
Growth hormone secretagogues are prohibited under WADA's S2 category. Competitive athletes subject to testing should not use them.
Peer-Reviewed Evidence
The Trials Behind the Protocol
Teichman et al., J Clin Endocrinol Metab (2006)
CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults.
Journal of Clinical Endocrinology & Metabolism
Raun et al., Eur J Endocrinol (1998)
Ipamorelin released GH with high selectivity and no significant rise in ACTH or cortisol.
European Journal of Endocrinology
Sigalos & Pastuszak, Sex Med Rev (2018)
Review of growth hormone secretagogues describing safety profile and clinical use cases.
Sexual Medicine Reviews
Titration Schedule
A Typical Dosing Ladder
Illustrative only. Your physician sets and adjusts your schedule based on tolerance, labs and rate of progress — escalation is never automatic.
| Phase | Dose | Clinical note |
|---|---|---|
| Weeks 1–2 | CJC-1295 100 mcg + Ipamorelin 200 mcg nightly | Assess sleep and tolerance. |
| Weeks 3–8 | CJC-1295 100 mcg + Ipamorelin 300 mcg nightly | 5 nights on, 2 nights off. |
| Weeks 9–12 | Maintain or adjust per IGF-1 | Dose set by follow-up labs, not by feel. |
| Reassess | — | Labs and physician review before a second cycle. |
Candidacy
Is This Right for You?
Often a Good Fit
- Adults over 30 with declining recovery and sleep quality
- Protecting lean mass during a GLP-1 protocol
- Consistent training with poor recovery between sessions
- Patients willing to complete follow-up labs
Not Appropriate If
- Active or recent cancer diagnosis
- Uncontrolled diabetes or poor glycemic control
- Pregnancy or breastfeeding
- Drug-tested competitive athletes
Safety Profile
Side Effects, Stated Plainly
Most side effects are dose-dependent and resolve with slower titration. Your care team is reachable by message, and holding a dose is always an option.
Common
- Injection-site redness or itching
- Water retention in the first weeks
- Vivid dreams or grogginess
- Transient hunger shortly after dosing
Serious — Contact Us Immediately
- Carpal tunnel-type numbness or tingling
- Reduced insulin sensitivity or rising fasting glucose
- Not appropriate with active or prior malignancy
- Prohibited in WADA-tested competition
Comparison
How It Compares
| Therapy | Mechanism | Avg. weight change | Frequency |
|---|---|---|---|
| CJC-1295 / Ipamorelin | GH secretagogue | — | Nightly |
| BPC-157 | Cytoprotective / angiogenic | — | Daily |
| TB-500 | Actin-binding, cell migration | — | 2x weekly |
FAQ
CJC-1295 / Ipamorelin Questions
Is this the same as HGH?+
No. HGH replaces the hormone directly. This protocol prompts your own pituitary to release it in natural pulses, which preserves the feedback loop.
Why at night?+
Your largest natural growth hormone pulse happens in deep sleep. Dosing at bedtime on an empty stomach works with that rhythm rather than against it.
Do I need labs?+
Yes. IGF-1, fasting glucose and A1c before starting and at follow-up. We do not continue a cycle without them.
Can I run it with a GLP-1?+
Yes, and it is a common pairing — the goal is losing fat while protecting lean mass. Your physician coordinates both protocols.
Also in the formulary
MW-102
Semaglutide
The clinical gold standard for appetite regulation.
View protocolMW-204
Tirzepatide
Dual incretin action for the deepest documented weight reduction.
View protocolMW-501
BPC-157
A gastric peptide studied for systemic tissue repair.
View protocolMW-502
TB-500
A synthetic fragment of Thymosin Beta-4 studied for soft-tissue recovery.
View protocolMW-701
NAD+ Injectable
A mitochondrial cofactor protocol for energy, focus and cellular repair.
View protocolMW-103
Semaglutide (Oral)
The same GLP-1 signal, taken as a daily oral dose instead of a weekly injection.
View protocolMW-702
MOTS-c
A mitochondrial-derived peptide studied for metabolic flexibility and exercise-like signaling.
View protocolMW-601
PT-141 (Bremelanotide)
An on-demand therapy that works on desire in the brain, not blood flow in the body.
View protocolMW-602
Semax / Selank
Intranasal peptides studied for focus, stress resilience and neurotrophic support.
View protocolMW-504
Sermorelin
The original growth hormone-releasing peptide — simpler and gentler than newer secretagogue combinations.
View protocolSee If CJC-1295 / Ipamorelin Is Right for You
A two-minute intake, reviewed by a licensed physician. No obligation, no membership fee.